Abigail Kegomoditswe Elias

Dr. Abigail Kegomoditswe Elias

NSW Health Pathology, Sydney, New South Wales, Australia
+1

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
YLYanqin Liu
Yanqin Liu
JCJohn Adrian Carver
John Adrian Carver
LHLam H. Ho
Lam H. Ho
AEAbigail Kegomoditswe Elias
Abigail Kegomoditswe Elias
Ian Francis MusgraveIan Francis Musgrave
Ian Francis Musgrave
TPTara Louise Pukala
Tara Louise Pukala
Protein misfolding causes serious biological malfunction, resulting in diseases including Alzheimer's disease, Parkinson's disease and cataract. Molecules which inhibit protein misfolding are a promising avenue to explore as therapeutics for the treatment of these diseases. In the present study, thioflavin T fluorescence and transmission electron microscopy experiments demonstrated that hemin prevents amyloid fibril formation of kappa-casein, amyloid beta peptide and α-synuclein by blocking β-sheet structure assembly which is essential in fibril aggregation. Further, inhibition of fibril formation by hemin significantly reduces the cytotoxicity caused by fibrillar amyloid beta peptide in vitro. Interestingly, hemin degrades partially formed amyloid fibrils and prevents further aggregation to mature fibrils. Light scattering assay results revealed that hemin also prevents protein amorphous aggregation of alcohol dehydrogenase, catalase and γs-crystallin. In summary, hemin is a potent agent which generically stabilises proteins against aggregation, and has potential as a key molecule for the development of therapeutics for protein misfolding diseases.

1 September 2014 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
AEAbigail Kegomoditswe Elias
Abigail Kegomoditswe Elias
DSDenis Scanlon
Denis Scanlon
Ian Francis MusgraveIan Francis Musgrave
Ian Francis Musgrave
JCJohn Adrian Carver
John Adrian Carver

17 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
AEAbigail Kegomoditswe Elias
Abigail Kegomoditswe Elias
Mark R. WilsonMark R. Wilson
Mark R. Wilson
JCJohn Adrian Carver
John Adrian Carver
Ian Francis MusgraveIan Francis Musgrave
Ian Francis Musgrave
Clusterin is a glycoprotein present at high concentrations in many extracellular fluids, including semen. Its increased expression accompanies disorders associated with extracellular amyloid fibril accumulation such as Alzheimer’s disease. Clusterin is an extracellular molecular chaperone which prevents the misfolding and amorphous and amyloid fibrillar aggregation of a wide variety of unfolding proteins. In semen, amyloid fibrils formed from a 39-amino acid fragment of prostatic acid phosphatase, termed Semen-derived Enhancer of Virus Infection (SEVI), potentiate HIV infectivity. In this study, clusterin potently inhibited the in vitro formation of SEVI fibrils, along with dissociating them. Furthermore, clusterin reduced the toxicity of SEVI to pheochromocytoma-12 cells. In semen, clusterin may play an important role in preventing SEVI amyloid fibril formation, in dissociating SEVI fibrils and in mitigating their enhancement of HIV infection.
1